Immunic (NASDAQ:IMUX) Coverage Initiated at HC Wainwright

HC Wainwright assumed coverage on shares of Immunic (NASDAQ:IMUX) in a report issued on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Immunic’s Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.95) EPS, FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.23) EPS.

IMUX has been the subject of a number of other reports. Leerink Partners restated an “outperform” rating and set a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. B. Riley began coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective for the company. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 16th. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Immunic has an average rating of “Buy” and an average price target of $11.80.

Immunic Stock Performance

Shares of IMUX opened at $1.20 on Monday. Immunic has a one year low of $0.97 and a one year high of $2.11. The stock has a market cap of $108.10 million, a P/E ratio of -0.98 and a beta of 1.88. The stock has a 50-day moving average of $1.36 and a two-hundred day moving average of $1.34.

Insider Buying and Selling at Immunic

In related news, Director Richard Alan Rudick bought 87,300 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp increased its stake in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the period. Virtu Financial LLC acquired a new position in shares of Immunic in the first quarter worth $25,000. Jane Street Group LLC increased its position in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares in the last quarter. Finally, Ikarian Capital LLC boosted its holdings in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the period. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.